FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387393335> ?p ?o ?g. }

• W4387393335 abstract "Abstract Nivasorexant, a selective orexin‐1‐receptor antagonist, has recently been assessed in the treatment of humans with binge‐eating disorder. Herein, the inhibitory potential of nivasorexant on cytochromes P450 (CYPs) 2C9, 2C19, and 3A4 was evaluated. Human liver microsomes/recombinant CYP enzymes were evaluated in vitro. In vivo, a single‐center, open‐label, fixed‐sequence study was performed in healthy adults to explore the effect of 100 mg nivasorexant administered twice daily (b.i.d.) on the pharmacokinetics (PK) of flurbiprofen (50 mg, CYP2C9), omeprazole (20 mg, CYP2C19), midazolam (2 mg, CYP3A4) making use of a cocktail approach. Plasma PK sampling was performed over 24 h on Day 1 (Cocktail alone), 8 (Cocktail + nivasorexant), and 15 (Cocktail + nivasorexant at steady state). Genotyping of subjects' CYPs was performed while safety and tolerability were also assessed. In vitro, nivasorexant inhibited CYP2C9, 2C19, and 3A4 in competitive inhibition assays with IC 50 values of 8.6, 1.6, and 19–44 μM, respectively, while showing a significant time‐dependent CYP2C19 inhibition. In 22 subjects, exposure to flurbiprofen, omeprazole, and midazolam was generally higher during concomitant single‐ (i.e., area under the plasma concentration–time curve [AUC] ratio increased by 1.04‐, 2.05‐, and 1.56‐fold, respectively) and repeated‐dose (i.e., AUC ratio increased by 1.47‐, 6.84‐, and 3.71‐fold, respectively) nivasorexant administration compared with the cocktail substrates administered alone. The most frequently reported adverse event was somnolence. According to regulatory guidance, nivasorexant is classified as a moderate CYP2C19 and weak CYP3A4 inhibitor after 1 day and as a weak CYP2C9, strong CYP2C19, and moderate CYP3A4 inhibitor after 8 days of 100 mg b.i.d. administration. Clinicaltrials.gov ID: NCT05254548." @default.
• W4387393335 created "2023-10-07" @default.
• W4387393335 creator A5037562729 @default.
• W4387393335 creator A5046806126 @default.
• W4387393335 creator A5058093690 @default.
• W4387393335 creator A5072257915 @default.
• W4387393335 creator A5077152954 @default.
• W4387393335 creator A5084451359 @default.
• W4387393335 date "2023-10-01" @default.
• W4387393335 modified "2023-10-18" @default.
• W4387393335 title "Effect of nivasorexant (<scp>ACT</scp>‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome <scp>P450</scp> probe substrates in vitro and in vivo using a cocktail approach in healthy subjects" @default.
• W4387393335 cites W1985137752 @default.
• W4387393335 cites W1986545656 @default.
• W4387393335 cites W1998069164 @default.
• W4387393335 cites W2001272039 @default.
• W4387393335 cites W2001672463 @default.
• W4387393335 cites W2007848784 @default.
• W4387393335 cites W2009045710 @default.
• W4387393335 cites W2026267674 @default.
• W4387393335 cites W2026551042 @default.
• W4387393335 cites W2027740042 @default.
• W4387393335 cites W2028912886 @default.
• W4387393335 cites W2031092738 @default.
• W4387393335 cites W2035787557 @default.
• W4387393335 cites W2061099365 @default.
• W4387393335 cites W2080228333 @default.
• W4387393335 cites W2083870238 @default.
• W4387393335 cites W2095380459 @default.
• W4387393335 cites W2101265962 @default.
• W4387393335 cites W2105664653 @default.
• W4387393335 cites W2105681476 @default.
• W4387393335 cites W2110969601 @default.
• W4387393335 cites W2134676888 @default.
• W4387393335 cites W2135711647 @default.
• W4387393335 cites W2137064401 @default.
• W4387393335 cites W2145759756 @default.
• W4387393335 cites W2156464193 @default.
• W4387393335 cites W2156481297 @default.
• W4387393335 cites W2175276690 @default.
• W4387393335 cites W2894958559 @default.
• W4387393335 cites W2901914704 @default.
• W4387393335 cites W2912252512 @default.
• W4387393335 cites W2982433938 @default.
• W4387393335 cites W3004867955 @default.
• W4387393335 cites W3008009497 @default.
• W4387393335 cites W3022479802 @default.
• W4387393335 cites W3034033771 @default.
• W4387393335 cites W3097325638 @default.
• W4387393335 cites W3178421081 @default.
• W4387393335 cites W787448140 @default.
• W4387393335 doi "https://doi.org/10.1002/prp2.1143" @default.
• W4387393335 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37800597" @default.
• W4387393335 hasPublicationYear "2023" @default.
• W4387393335 type Work @default.
• W4387393335 citedByCount "0" @default.
• W4387393335 crossrefType "journal-article" @default.
• W4387393335 hasAuthorship W4387393335A5037562729 @default.
• W4387393335 hasAuthorship W4387393335A5046806126 @default.
• W4387393335 hasAuthorship W4387393335A5058093690 @default.
• W4387393335 hasAuthorship W4387393335A5072257915 @default.
• W4387393335 hasAuthorship W4387393335A5077152954 @default.
• W4387393335 hasAuthorship W4387393335A5084451359 @default.
• W4387393335 hasBestOaLocation W43873933351 @default.
• W4387393335 hasConcept C109650736 @default.
• W4387393335 hasConcept C112705442 @default.
• W4387393335 hasConcept C140840227 @default.
• W4387393335 hasConcept C150903083 @default.
• W4387393335 hasConcept C170493617 @default.
• W4387393335 hasConcept C181199279 @default.
• W4387393335 hasConcept C185592680 @default.
• W4387393335 hasConcept C207001950 @default.
• W4387393335 hasConcept C22979827 @default.
• W4387393335 hasConcept C2776885963 @default.
• W4387393335 hasConcept C2777498785 @default.
• W4387393335 hasConcept C526171541 @default.
• W4387393335 hasConcept C55493867 @default.
• W4387393335 hasConcept C71924100 @default.
• W4387393335 hasConcept C86803240 @default.
• W4387393335 hasConcept C98274493 @default.
• W4387393335 hasConceptScore W4387393335C109650736 @default.
• W4387393335 hasConceptScore W4387393335C112705442 @default.
• W4387393335 hasConceptScore W4387393335C140840227 @default.
• W4387393335 hasConceptScore W4387393335C150903083 @default.
• W4387393335 hasConceptScore W4387393335C170493617 @default.
• W4387393335 hasConceptScore W4387393335C181199279 @default.
• W4387393335 hasConceptScore W4387393335C185592680 @default.
• W4387393335 hasConceptScore W4387393335C207001950 @default.
• W4387393335 hasConceptScore W4387393335C22979827 @default.
• W4387393335 hasConceptScore W4387393335C2776885963 @default.
• W4387393335 hasConceptScore W4387393335C2777498785 @default.
• W4387393335 hasConceptScore W4387393335C526171541 @default.
• W4387393335 hasConceptScore W4387393335C55493867 @default.
• W4387393335 hasConceptScore W4387393335C71924100 @default.
• W4387393335 hasConceptScore W4387393335C86803240 @default.
• W4387393335 hasConceptScore W4387393335C98274493 @default.
• W4387393335 hasIssue "5" @default.
• W4387393335 hasLocation W43873933351 @default.
• W4387393335 hasLocation W43873933352 @default.
• W4387393335 hasOpenAccess W4387393335 @default.
• W4387393335 hasPrimaryLocation W43873933351 @default.

• next